Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 187 clinical trials
featured
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy.  

daratumumab
refractory multiple myeloma
  • 71 views
  • 28 May, 2020
  • 28 locations
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

All patients with multiple myeloma (MM) are destined to relapse even with the best available approved agents. Median OS from diagnosis in the current era is reported at 5.4 years. Given that myeloma remains an incurable disease, future improved OS is therefore reliant on the expansion of salvage options for …

  • 22 views
  • 21 Jan, 2021
  • 1 location
Isatuximab in Combination With Novel Agents in RRMM

or refractory multiple myeloma (RRMM). Part 2: To demonstrate the clinical benefit of SAR439459 combined with isatuximab and dexamethasone in terms of rate of very good partial

  • 0 views
  • 27 Apr, 2021
  • 9 locations
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.

  • 18 views
  • 25 Apr, 2021
  • 113 locations
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 29 Apr, 2021
  • 37 locations
Dexamethasone Carfilzomib & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of wild-type reovirus (pelareorep) when given together with dexamethasone, carfilzomib, and nivolumab in treating patients with multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of …

ejection fraction
proteasome inhibitor
bortezomib
oophorectomy
refractory multiple myeloma
  • 21 views
  • 28 Jan, 2021
  • 2 locations
RAPA-201 T Cell Therapy for Relapsed Refractory Multiple Myeloma

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter Phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at

  • 0 views
  • 02 Feb, 2021
  • 1 location
AGENT-797 in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase I, open-label, dose-escalation, single arm study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in subjects with relapsed/refractory MM, as well as define the RP2D.

  • 0 views
  • 14 May, 2021
  • 1 location
Pomalidomide Ixazomib and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple

neutrophil count
cyclophosphamide
platelet count
dexamethasone
bortezomib
  • 2 views
  • 25 Jan, 2021
  • 18 locations
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Prospective multicenter phase 2 study using PAD and Thal/Dex combination sequentially.

velcade
dexamethasone
thalidomide
refractory multiple myeloma
cell transplantation
  • 6 views
  • 07 Nov, 2020
  • 1 location